EF Hutton initiated coverage of Lumos Pharma with a Buy rating and $16 price target. Lumos is delivering on the promise of an oral growth hormone, a secretagogue, that mimics the natural action of growth hormone, the analyst tells investors in a research note. The firm sees the potential for LUM-201 to “change the existing paradigm” in the $5B U.S. growth hormone marketplace.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUMO:
- Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
- Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
- Lumos Pharma reports Q2 EPS (93c), consensus ($1.24)
- Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
- LUMO Upcoming Earnings Report: What to Expect?